Drug Trial Radar · NCT05188313
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Last checked: Nov 20, 2026Latest source record: Jun 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
Mar 9, 2022
Primary completion
Jul 2027
Study completion Feb 2037
Sponsor
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0). Also, no targeted treatment options are currently available, hampering personalized treatment for this patient population. TRAP-2 aims to address these needs by investigating whether addition of trastuzumab and pertuzumab to standard of care improves survival of patients with resectable HER2 positive esophageal adenocarcinoma (HER2+ EAC). Patients with HER2+ EAC will be randomised to neoadjuvant chemoradiation according to the CROSS regimen or CROSS + TRAstuzumab and Pertuzumab. Primary outcome is overall survival.
Conditions
- Esophageal Cancer
- Esophageal Adenocarcinoma
Interventions
TrastuzumabDrug
Intravenous administration of study drug
PertuzumabDrug
Intravenous administration of study drug
PaclitaxelDrug
Intravenous administration of study drug
CarboplatinDrug
Intravenous administration of study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: 5.5. years (maximum follow-up time)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Academic Medical Center
Amsterdam, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.